ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2639

Pathological Relevance of T Follicular Helper Cell and Plasmablast in Patients with Systemic Lupus Erythematosus

Shingo Nakayamada1, Satoshi Kubo2, Maiko Yoshikawa2, Yusuke Miyazaki2, Shigeru Iwata3, Ippei Miyagawa4, Shunsuke Fukuyo5, Kazuhisa Nakano1 and Yoshiya Tanaka6, 1First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 2The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 3First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 4University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 5University of Occupational and Environmental Health, Japan, Fukuoka, Japan, 6The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Plasmablasts, SLE and T cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Systemic Lupus Erythematosus – Human Etiology and Pathogenesis Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Increasing evidence points to immunological heterogeneity in the pathogenesis of SLE. Indeed, targeted therapy for SLE showed considerable variability of efficacy. Thus, it seems to be important to explore the characteristic and interaction among the immune cell phenotypes in this disease. The aim of this study was to assess the comprehensive peripheral immunophenotyping in a correlation with clinical manifestations in patients with SLE.

Methods: Peripheral blood mononuclear cells were obtained from 143 SLE patients and 49 healthy controls (HC) and the phenotype of circulating B, T, NK and dendritic cells was defined based on flow cytometric analysis for human immune system termed “the Human Immunology Project”. The correlation of immune cell phenotypes with clinical characteristics and responsiveness to immunosuppressive therapies, such as cyclophosphamide, mycophenolate mofetil, or calcineurin, in addition to high-dose glucocorticoids, were evaluated.

Results: The frequency of CD3+CD4+CXCR5+ICOS+CD69+ activated T follicular helper (Tfh) cell, but not CD3+CD4+CXCR3+CCR6– Th1 cell and CD3+CD4+CXCR3–CCR6+ Th17 cell, were higher in SLE than that in HC (mean 0.4 vs 0.2, p=0.03). The frequency of CD19+ CD20+IgD–CD27+ class-switched memory B cell and CD19+CD20+IgD–CD27– double negative B cell were higher in SLE than that in HC (mean 23.6 vs 13.2 and 10.7 vs 5.5, p=0.03 and p=0.04, respectively). The largest difference relative to the HC was observed in the proportion of CD19+CD20–CD27+CD38+ plasmablast, which was higher in SLE (mean 16.2 vs 3.3, p=001) and correlated with BILAG index (r=0.24, p<0.001). The proportion of activated Tfh cell significantly correlated with serum IgG level (r=0.20, p=0.02) and with serum anti-Sm antibody level (r=0.26, p=0.01). Among helper T cell subsets (Th1, Th17, Treg and Tfh), the proportion of Tfh cell or activated Tfh cell showed positive correlation with that of plasmablast (r=0.21, p=0.02). Treatment resulted in significant decreased proportions of plasmablast and Tfh cell (plasmablast; mean 17.6 to 10.1, p<0.01, Tfh; mean 1.1 to 0.7, p<0.01). The percentage of patients who showed treatment resistance was highest among patients with high percentage of Tfh cell (p=0.03).

Conclusion: Peripheral immunophenotyping indicated the pathological relevance of Tfh cell and plasmablast in patients with SLE, i.e. activation of Tfh cell correlated with autoantibody production while plasmablast did with disease activity of SLE. The peripheral immunophenotyping might be useful in evaluating the pathogenesis and in determining the therapeutic target of each patient.


Disclosure: S. Nakayamada, Bristol-Myers Squibb, 8; S. Kubo, Bristol-Myers Squibb, 8,Pfizer Inc, 8,Takeda Pharmaceutical Company Ltd, 8; M. Yoshikawa, None; Y. Miyazaki, None; S. Iwata, None; I. Miyagawa, None; S. Fukuyo, None; K. Nakano, None; Y. Tanaka, Mitsubishi-Tanabe, Takeda, Bristol-Myers, Chugai, Astellas, AbbVie, MSD, Daiichi-Sankyo, Pfizer, Kyowa- Kirin, Eisai, Ono, 2,Daiichi-Sankyo, Astellas, Pfizer, Mitsubishi-Tanabe, Bristol-Myers, Chugai, YL Biologics, Eli Lilly and Company, Sanofi, Janssen, UCB, 8.

To cite this abstract in AMA style:

Nakayamada S, Kubo S, Yoshikawa M, Miyazaki Y, Iwata S, Miyagawa I, Fukuyo S, Nakano K, Tanaka Y. Pathological Relevance of T Follicular Helper Cell and Plasmablast in Patients with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/pathological-relevance-of-t-follicular-helper-cell-and-plasmablast-in-patients-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pathological-relevance-of-t-follicular-helper-cell-and-plasmablast-in-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology